{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "PARK2 mutations in cancer decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, linking PARK2 mutations to decreased E3 ligase activity and cyclin E dysregulation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Cancer-specific mutations abrogate the growth-suppressive effects of the PARK2 protein.",
          "judgment": "Yes",
          "reasoning": "The assay used effectively models the disease pathogenesis by demonstrating the growth-suppressive effects of PARK2 and how mutations abrogate these effects.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Expression of WT but not mutant PARK2 into cells from the DBTRG line resulted in a reduction in the rate of cell growth.",
          "judgment": "Yes",
          "reasoning": "The paper describes the use of controls (WT vs. mutant PARK2) and replicates, indicating a valid assay setup.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "WT PARK2 decreased tumor growth in vivo, a property that was reduced by the cancer-specific mutations.",
          "judgment": "Yes",
          "reasoning": "The use of WT PARK2 as a control and the demonstration of reduced tumor growth with cancer-specific mutations meet the criteria for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "PARK2 mutations in cancer decrease PARK2's E3 ligase activity, compromising its ability to ubiquitinate cyclin E and resulting in mitotic instability.",
          "judgment": "Yes",
          "reasoning": "The evidence strongly supports the pathogenic role of PARK2 mutations in cancer through their impact on E3 ligase activity and cyclin E regulation.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study demonstrates clear functional consequences of PARK2 mutations, including decreased E3 ligase activity and cyclin E dysregulation, but does not provide OddsPath calculations.",
          "judgment": "Yes",
          "reasoning": "Given the clear functional impact and the use of multiple controls and replicates, the evidence supports a moderate strength rating despite the lack of OddsPath calculations.",
          "next_step_or_outcome": "Assign PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The PARK2 R42C mutation is assessed as PS3_moderate due to its clear impact on E3 ligase activity and cyclin E regulation, supported by controlled experiments and replicates, albeit without OddsPath calculations."
    }
  ]
}